BC
ATRS

Bridgefront Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Bridgefront Capital’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,061
Closed -$87K – 995
2021
Q1 		$87K Buy
+21,061
New +$91.3K 0.03% 627

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

Bridgefront Capital's ATRS Position: Q2 2021 in Review

Bridgefront Capital sold out of Antares Pharma, Inc. (ATRS) in Q2 2021, closing a stake of 21,061 shares — an estimated $87K sold.

Bridgefront Capital first reported a position in ATRS in Q1 2021 and held it in 1 quarter. The position peaked at $87K in Q1 2021. 175 funds tracked by Wall St. Rank hold ATRS as of Q2 2021.

  • Bridgefront Capital reported no remaining Antares Pharma, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bridgefront Capital sold 21,061 Antares Pharma, Inc. shares in Q2 2021, an estimated $87K.
  • Bridgefront Capital first reported a position in Antares Pharma, Inc. in Q1 2021 and held it in 1 quarter.
  • Bridgefront Capital's Antares Pharma, Inc. position peaked at $87K in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.